Abstract

Noninvasive long-term imaging of therapeutic cells in preclinical models can be achieved through introducing a reporter gene into the cells of interest. Despite important recent developments such as gene editing, cell engineering based on lentiviruses remains a mainstream tool for gene transfer applicable to a variety of different cell types.In this chapter, we describe how to use lentivirus-based genetic engineering to render different candidate cell therapies in vivo traceable by radionuclide imaging. We illustrate this reporter gene technology using the sodium iodide symporter (NIS), which is compatible with both positron emission tomography (PET) and single-photon emission computed tomography (SPECT). For preclinical experimentation, we fused NIS with a suitable fluorescent protein such as monomeric GFP or RFP to streamline cell line generation and downstream analyses of ex vivo tissue samples. We present protocols for reporter gene engineering of human cardiac progenitor cells, regulatory T cells, and effector T cells as well as for the characterization experiments required to validate NIS-fluorescent protein reporter function in these candidate therapeutic cells.

Original languageEnglish
Pages (from-to)303-330
Number of pages28
JournalMethods in molecular biology (Clifton, N.J.)
Volume2729
DOIs
Publication statusPublished - 2024

Keywords

  • Humans
  • Positron-Emission Tomography/methods
  • Symporters/genetics
  • Tomography, Emission-Computed, Single-Photon
  • Genetic Engineering

Fingerprint

Dive into the research topics of 'Genetic Engineering of Therapeutic Cells with the Sodium Iodide Symporter (NIS) to Enable Noninvasive In Vivo Therapy Tracking'. Together they form a unique fingerprint.

Cite this